15 drugmakers with the biggest share price gains this year

Drugmakers of all sizes posted strong share price gains in the second quarter of 2020, according to EvaluatePharma's "Pharma, Biotech & Medtech Half-Year Review 2020." 

In the first half of 2020, global drugmaker stocks had grown in value over what they were at the end of 2019. Companies involved in finding COVID-19 treatments had the biggest gains. 

Fifteen drugmakers with the biggest share price gains in 2020: 

  1. Novavax — 1,994 percent share price gain ($4.73 billion market cap gain)

  2. Adaptimmune — 734 percent share price gain ($1.41 billion market cap gain)

  3. Inovio Pharmaceuticals —717 percent share price gain (3.93 billion market cap gain)

  4. Mesoblast — 708 percent share price gain ($0.47 billion market cap gain)

  5. Cytodyn — 468 percent share price gain ($2.61 billion market cap gain)

  6. Arcturus Therapeutics — 330 percent share price gain ($0.79 billion market cap gain)

  7. Moderna — 228 percent share price gain (17.32 market cap gain)

  8. BioNTech — 100 percent share price gain ($7.47 billion market cap gain)

  9. Samsung Biologics — 79 percent share price gain ($17.71 billion market cap gain)

  10. Chugai — 72 percent share price gain ($37.70 billion market cap gain)

  11. Regeneron  — 66 percent share price gain ($28.49 billion market cap gain)

  12. Lonza — 42 percent share price gain ($11.98 billion market cap gain)

  13. Eli Lilly — 25 percent share price gain ($30.84 billion market cap gain)

  14. AbbVie — 11 percent share price gain ($42.09 billion market cap gain)

  15. AstraZeneca — 6 percent share price gain ($7.99 market cap gain)

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars